High-dose individualized antithymocyte globulin with therapeutic drug monitoring in high-risk cord blood transplant
Rick Admiraal(NHS Blood and Transplant), Stefan Nierkens(Utrecht University), L. Ebskamp(University Medical Center Utrecht), Caroline A. Lindemans(University Medical Center Utrecht), Clara TMM de Kanter(University of Curaçao), Alwin D. R. Huitema(The Netherlands Cancer Institute), Marc Bierings(University Medical Center Utrecht), A. Birgitta Versluijs(NHS Blood and Transplant), Amelia M. Lacna(University Medical Center Utrecht), Jaap Jan Boelens(Wilhelmina Children's Hospital)
Cited by 2
Related Papers
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451